106245-03-8

Basic information

• Product Name: 1-(2-(benzyloxy)-4-fluorophenyl)ethanone
• Synonyms: 1-(2-(benzyloxy)-4-fluorophenyl)ethanone;1-[4-Fluoro-2-(phenylmethoxy)phenyl]ethanone;1-(2-(Benzyloxy)
• CAS NO: 106245-03-8
• Molecular Formula: C₁₅H₁₃FO₂
• Molecular Weight: 244
• Mol File: 106245-03-8.mol

Chemical Properties

• Melting Point: 58-59℃
• Appearance: /
• Density: 1.163
• CAS DataBase Reference: 1-(2-(benzyloxy)-4-fluorophenyl)ethanone(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(2-(benzyloxy)-4-fluorophenyl)ethanone(106245-03-8)
• EPA Substance Registry System: 1-(2-(benzyloxy)-4-fluorophenyl)ethanone(106245-03-8)

Safety Data

• Hazardous Substances Data: 106245-03-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Synthesis:
1-(2-(Benzyloxy)-4-fluorophenyl)ethanone is used as a building block for the synthesis of various pharmaceuticals and organic compounds. Its unique structure contributes to the development of new drugs with potential therapeutic applications.
Used in Chemical Reactions:
As a reagent, 1-(2-(Benzyloxy)-4-fluorophenyl)ethanone is utilized in chemical reactions to facilitate specific transformations or to produce desired products, taking advantage of its reactive ketone and fluorine-containing groups.
Used in Organic Chemistry:
1-(2-(Benzyloxy)-4-fluorophenyl)ethanone serves as a starting material in the preparation of complex organic molecules, where its structural features can be further elaborated upon to create a diverse range of compounds for various applications.
Used in the Chemical Industry:
In the chemical industry, 1-(2-(Benzyloxy)-4-fluorophenyl)ethanone may be employed as an intermediate in the production of specialty chemicals, materials, or other high-value products, leveraging its unique structural attributes.

Upstream product

• 1481-27-2 4-Fluoro-2-hydroxyacetophenone 
• 100-44-7 benzyl chloride 
• 100-39-0 benzyl bromide 
• 67-64-1 acetone 

Downstream Products

• 1193392-96-9 ethyl 4-[2-(benzyloxy)-4-fluorophenyl]-2,4-dioxobutanoate 
• 1310825-33-2 7,4'-difluoroisoflavone 
• 1310825-34-3 2'-benzyloxy-4,4'-difluorochalcone 
• 1310825-35-4 2'-benzyloxy-4-nitro-4'-fluorochalcone 
• 1193392-70-9 (7-fluoro-3,4-dihydro-2h-chromen-2-yl)methyl 4-methylbenzenesulfonate 
• 1193392-97-0 ethyl 4-(4-fluoro-2-hydroxyphenyl)-2-hydroxybutanoate 
• 1374846-24-8 4-[1-(2-benzyloxy4-fluoro-benzoyl)-2-dimethylamino-vinyl]-piperazine-1-carboxylic acid tert-butyl ester 
• 719288-27-4 4-[3-(2-benzyloxy4-fluoro-phenyl)-1H-pyrazol-4-yl]-piperazine-1-carboxylic acid tert-butyl ester 
• 719288-26-3 2'-(benzyloxy)-2-[4-(tert-butoxycarbonyl)piperazin-1-yl]-4'-fluoroacetophenone 
• 1189550-83-1 2-(benzyloxy)-4-fluorophenyl acetate 
• 719288-25-2 1-(2-(benzyloxy)-4-fluorophenyl)-2-bromoethan-1-one 

Relevant articles and documents

FLUOROPHENYL BETA-HYDROXYETHYLAMINES AND THEIR USE IN THE TREATMENT OF HYPERGLYCAEMIA

There is herein provided a compound of formula (I).

Determination of the Absolute Configuration and a Practical Chiral Synthesis of 5-[5-(1-Methylethoxy)pyridin-2-yl]-5-methyl imidazolidine-2,4-dione as a Novel Liver X Receptor β-Selective Agonist

We determined that the absolute configuration of 5-[5-(1-methylethoxy)pyridin-2-yl]-5-methylimidazolidine-2,4-dione (hydantoin) is the (S)-form for the liver X receptor (LXR) β-selective agonist through X-ray crystal structure analysis of the hydantoin hydrogen bromide salt. Furthermore, we established a practical synthesis of the chiral hydantoin with 99% ee by the optical resolution of racemic methyl 2-amino-2-[5-(1-methylethoxy)pyridin-2-yl]propanoate with d-(-)-mandelic acid on a multi-kilogram scale. Finally, we improved the synthesis method of the LXR β-selective agonist.

Synthesis of fluorine-containing 3-hydroxyflavanones and isoflavones

Fluorine-containing 3-hydroxyflavanones and isoflavones were synthesized by epoxidation of F-containing chalcones by hydrogen peroxide under basic conditions and subsequent intramolecular cyclization of the resulting epoxides using BF3·Et2O. The ratio of products depended on the presence and position of the F atom.

HYDROXYQUINOXALINECARBOXAMIDE DERIVATIVE

The present invention provides a novel hydroxyquinoxaline carboxamide derivative that is useful for preventing and/or treating blood coagulation disorders. A compound represented by formula (i), or a pharmacologically acceptable salt thereof: wherein, each of R1 and R2 independently represents a group such as a hydrogen atom or a halogen atom; R3 represents a group such as a hydrogen atom; each of R4 and R5 independently represents a group such as a hydrogen atom, a halogen atom or a C1-4 alkyl group; each of R6 and R7 independently represents a hydrogen atom or a C1-4 alkyl group; X represents a group such as a C3-10 cycloalkyl group, C6-10 aryl group or a 5- to 10-membered heterocyclic group, which may be substituted with substituent(s) selected from substituent group α; Y represents a group such as -CO-, -O- or -NRa-, and Ra represents a group such as a hydrogen atom or a C1-4 alkyl group.

MODULATORS OF DOPAMINE NEUROTRANSMISSION

The present invention relates to novel 1-(2,3-dihydro-1,4-benzodioxin-2-yl)-methanamine derivatives, useful as modulators of dopamine neurotransmission, and more specifically as dopaminergic stabilizers. In other aspects the invention relates to the use o

PYRAZOLE COMPOUNDS

Compounds of formula (IA) or (IB) or a salt, N-oxide, hydrate or solvate thereof are inhibitors of HSP90, and are of value in the treatment of diseases responsive to HSP90 inhibition such as cancers. In the formulae, Ar is an aryl, aryl(C1-C6 alkyl), aryl(C1-C6 alkyl), heteroaryl, heteroarylaryl(C1-C6 alkyl), or heteroarylaryl(C1-C6 alkyl) group, any of which being optionally substituted in the aryl or heteroaryl part thereof; R1, is hydrogen or optionally substituted Cl-C6 alkyl; R2 is hydrogen, optionally substituted cycloalkyl, cycloalkenyl, C1-C6 alkyl, C1-C6 alkenyl, or Cl-C6 alkynyl; or a carboxyl, carboxamide or carboxyl ester group; and ring A is a non aromatic carbocyclic or heterocyclic ring wherein (i) a ring carbon is optionally substituted, and/or (ii) a ring nitrogen is optionally substituted by a group of formula -(Alk1)p (Cyc)n-(Alk3)m-(Z)r (Alk2)s Q where Alk1, Alk2 and Alk3 are optionally substituted C1-C3 alkyl, Cyc is an optionally substituted carbocyclic or heterocyclic radical; m, n, p, r and s are independently 0 or 1, Z is -0-, -S-, -(C=O)-, -S02-, -C(=O)O-, -OC(=O)-, -NW-, -C(=O)NRA-, -NRAC(=O)-, -SO2NRA- , or -NRASO2- wherein RA is hydrogen or C1-C6 alkyl, and Q is hydrogen or an optionally substituted carbocyclic or heterocyclic radical.

Antidepressive substituted N-[(4-piperidinyl)alkyl] bicyclic condensed oxazol- and thiazolamines

Novel substituted N-[(4-piperidinyl)alkyl] bicyclic condensed oxazol- and thiazolamines useful as anti-depressives, in the treatment of Parkinson's disease and in the treatment of diseases related with disturbed enterokinesia.